13-Deoxycarminomycin, a new biosynthetic anthracycline.
A new antitumor antibiotic, 13-deoxycarminomycin, has been isolated from the anthracycline complex produced by Streptomyces peucetius var. carminatus (ATCC 31502), a biochemical mutant of Streptomyces peucetius var. caesius, the doxorubicin-producing microorganism. The new anthracycline, showing antibacterial and cytotoxic activity in vitro, was found active against P-388 murine leukemia.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000032:analysis* / Q000096:biosynthesis / Q000494:pharmacology; D002360:Carubicin / Q000031:analogs & derivatives / Q000032:analysis / Q000096:biosynthesis / Q000494:pharmacology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D005285:Fermentation; D006367:HeLa Cells; D006801:Humans; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D009279:Naphthacenes / Q000032:analysis / Q000096:biosynthesis / Q000494:pharmacology; D013302:Streptomyces / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C046355:13-deoxycarminomycin; D002360:Carubicin